I find interesting correlations between the Investigator Initiated Trial (IIT) results that former Board Member Kevin Xie's 'Gracell' just announced, compared to the PREACH-M trial results recently announced for Humanigen's lenzilumab. Gracell: https://www.sec.gov/Archives/edgar/data/1826492/000110465923126860/tm2332578d1_ex99-1.htm Humanigen: https://ash.confex.com/ash/2023/webprogram/Paper179706.html